

2nd UAE International Conference on Antimicrobial Resistance (ICAMR)

21st & 22nd March, 2019

Dubai, United Arab Emirates www.ICAMR-UAE.com | #ICAMRUAE | #IPEvents

AMR@InfoPlusEvents.com



How Do Bundles Improve HAI

Dr Faryal Khamis, M.D. Adult Infectious Diseases and Medical Microbiology The Royal Hospital, Oman



Healthcare Associated Infection

- Poor clinical outcome
- Longer hospital stay
- More resources and effort spent
 - Money
 - Manpower
 - Materials
 - Methods
 - Management

and enort spent

you can get an infection in the hospital while

you're being treated

for something else

"Your infection may be antibiotic-resistant, but let's see how it responds to intensive litigation."



- Care "bundles" are simple sets of evidence-based practices that, when implemented collectively, improve the reliability of their delivery and improve patient outcomes.¹
- A number of specific bundles can be implemented at healthcare facilities to prevent HAI infection, reduce unnecessary antibiotic prescribing, and limit the development of antibiotic resistance.

1. Haraden C. Institute for Healthcare Improvement Website: What is a bundle? <u>http://www.ihi.org/knowledge/Pages/ImprovementStories/WhatIsaB</u>undle.aspx.



Why Care Bundles



Antimicrobial

Resistance (ICAMR)

- **Reliable** and **consistent** care systems.¹
- Simple 3-5 elements that are clear and concise.¹
- Promote multi-disciplinary collaboration, consensus and endorsement.^{1/2}
- Help to deliver the best possible care for patients undergoing treatments with inherited risks.²

1. Resar R, Griffin FA, Haraden C, Nolan TW. Using Care Bundles to Improve Health Care Quality. IHI Innovation Series White Paper: Institute for Healthcare Improvement; 2012

2. Resar R, Pronovost P, Haraden C, et al. Using A Bundle Approach to Improve Ventilator Care Processes and Reduce Ventilator-Associated Pneumonia. Jt Comm J Qual Patient Saf. 2005; 31(5):243–8.

So, A Bundle



- Based on randomized controlled trials, level 1 evidence
- Focuses on how to deliver the best care- not what the care should be



What's the difference between a bundle and a checklist?

- A checklist can be very helpful and an important vehicle for ensuring safe and reliable care.
- The elements in a checklist are often a mixture of nice-to-do tasks or processes (useful and important but not evidence-based changes) and have-to-do processes (proven by randomized control trials).

• A checklist may also have many, many elements.



What's the difference between a bundle and a checklist?

- There's also a level of accountability tied to a bundle that you don't always have with a checklist.
- An identified person or team owns it. A checklist might be owned by everybody on a floor or a team, but in reality, when it's owned by everyone – nobody owns it.
- Things don't always get done.
 - So maybe the pharmacist does one thing in a checklist, a nurse another, the doctor something else, but in reality it's no one's job at the end of the day.
- A bundle is a person or a team's responsibility period.
 - It's their job at a certain point and time during rounds every single day, possibly.
 - It's very clear who has to do what and when, within a specific time frame.
 - The accountability and focus give a bundle a lot of its power.



Who Can Use Care Bundles

- ICAMR UAE 2019
- Anyone in any clinical setting with the agreement of the clinical team leaders
- Infection Control Team should offer support with regard to implementation and advice on data collection, analysis and feedback



Implementation and Performance Measures



Resar R, Griffin FA, Haraden C, Nolan TW. Using Care Bundles to Improve Health Care Quality. IHI Innovation Series White Paper: Institute for Healthcare Improvement; 2012

In successful bundle implementation each element of the bundle must be implemented collectively with complete consistency to achieve the most favorable outcomes.¹

- Appropriately followed
- Entrenched in patient care culture
- "Positive habit forming behavior"
- Recorded and evaluated to assess compliance ²
- Teamwork ³

1. Resar R, Griffin FA, Haraden C, Nolan TW. Using Care Bundles to Improve Health Care Quality. IHI Innovation Series White Paper: Institute for Healthcare Improvement; 2012

2. Richards GA, Brink AJ, Messina AP, et al. Stepwise Introduction of the 'Best Care Always' Central-Line-Associated Bloodstream Infection Prevention Bundle in a Network of South African hospitals. J Hosp Infect. 2017; 97(1):86–92. doi: 10.1016/j.jhin.2017.05.013.

3. Jain M, Miller L, Belt D, et al. Decline In ICU Adverse Events, Nosocomial Infections and Cost Through a Quality Improvement Initiative Focusing on Teamwork 2nd UAE and Culture Change. Qual Saf Health Care. 2006; 15(4):235–9.

ALL NOTHING



on Antimicrobial Resistance (ICAMR) Process steps for designing care bundles



Flowchart for designing new care bundles

International Journal for Quality in Health Care, Volume 29, Issue 2, 02 February 2017, Pages 163–175.

Types of Care Bundles

- CVC Care Bundle
- PVC Care Bundle
- Surgical Site Infection Bundle
- Urinary Catheter Care Bundle
- Clostridium difficile Care Bundle
- Ventilator Assisted Pneumonia Care Bundle
- Environmental cleaning Care Bundle
- Infection control Care Bundle

••••••

•



Bundles for the prevention of central line-associated bloodstream infections (CLABSI)

- CLABSIs are responsible for excess mortality and morbidity, prolonged hospital stays and increased costs¹
- CLABSI incidence is higher in low income countries¹
- Implementation of central line insertion and maintenance bundles reduces the incidence of CLABSI in ICUs and non- ICU settings^{2'3}

 1.Ista E, van der Hoven B, Kornelisse RF, et al. Effectiveness of Insertion and Maintenance Bundles to Prevent Central-Line-Associated Bloodstream Infections in Critically III Patients of All Ages: a Systematic Review and Meta-Analysis. Lancet Infect Dis. 2016; 16(6):724–34. doi: 10.1016/S1473-3099(15)00409-0.
 2.Dumyati G, Concannon C, van Wijngaarden E, et al. Sustained Reduction of Central Line-Associated Bloodstream Infections Outside the Intensive Care Unit with a Multimodal Intervention Focusing on Central Line Maintenance. Am J Infect Control. 2014; 42(7):723–30. doi: 10.1016/j.ajic.2014.03.353.
 3.Klintworth G, Stafford J, O'Connor M, et al. Beyond the Intensive Care Unit Bundle: Implementation of a Successful Hospital-Wide Initiative to Reduce Central Line-Associated Bloodstream Infections. Am J Infect Control. 2014; 42(6):685–7. doi: 10.1016/j.ajic.2014.02.026.

> on Antimicrobial Resistance (ICAMR)

Insertion Bundle

- Hand Hygiene
- Maximal sterile barrier precautions (surgical mask, sterile gloves, cap, sterile gown)
- Full body sterile drape
- Skin cleaning with alcohol-based chlorhexidine (rather than iodine)
- Avoidance of the femoral vein for central venous access in adult patients; use of subclavian rather than jugular veins

Maintenance Bundle

Hand Hygiene Daily review of line Disinfect catheter hubs, ports, connectors, etc., before using the catheter Ensure dressing is intact Change dressings and disinfect site with alcohol-based chlorhexidine every 5-7 days (change earlier if soiled)

 A multi-modal approach including hand hygiene, clinician and nurse education, and performance of surveillance and feedback of CLABSI rates







Effectiveness of insertion and maintenance bundles to prevent central-line-associated bloodstream infections in critically ill patients of all ages: a systematic review and meta-analysis

Erwin Ista, Ben van der Hoven, René F Kornelisse, Cynthia van der Starre, Margreet CVos, Eric Boersma, Onno K Helder

Lancet Infect Dis 2016;16:724-34

	Weight	IRR (95% CI)	(Figure 1 continued)	Weight	IRR (95% CI)
Eggimann (2000) ⁴⁰	1-3	0-24 (0-13-0-45)	Seddon (2011)75	0-8	0.30 (0.11-0.84)
Yoo (2001) ⁸⁵	0-4	0-30 (0-05-1-63)	Speroff (2011) ⁷⁷	1.9	1.03 (0.84-1.24)
Rosenthal (2003) ⁷²	1.7	0-23 (0-16-0-34)	Boutaric (2012) ³⁰⁵	1-4	0.65 (0.36-1.16)
Warren (2003)82	1.2	0-43 (0-22-0-86)	Holzmann-Pazgal (2012) ³⁰⁹ -	1-8	0-35 (0-27-0-45)
Coopersmith (2004) ³⁷	1-3	0-81 (0-45-1-45)	Lin (2012) ⁵⁵	1-4	0.53 (0.31-0.91)
Warren (2004) ⁸⁵	1.7	0-59 (0-40-0-86)	Marsteller (2012) ⁶⁰	1-8	0.46 (0.34-0.63)
Higuera (2005)46	1.5	0-42 (0-27-0-66)	Paula (2012)56	1-1	0-34 (0-16-0-71)
Lobo (2005) ⁵⁶	1.4	0-59 (0-34-1-04)	Payne (2012) ¹¹²	1.7	0.42 (0.29-0.61)
Wall (2005) ⁸⁰	1.0	0-54 (0-22-1-32)	Richardson (2012) ⁷¹	0.8	0.28 (0.09-0.81)
Jain (2006)50	1.3	0-52 (0-28-0-95)	Rosenthal (2012) ¹⁰¹	1.1	0.48 (0.23-1.01)
Shannon (2006)76	1.0	0-11 (0-05-0-27)	Sohail Ahmed (2012) ³⁰²	1.6	0.56 (0.36-0.87)
Warren (2006) ^m	1.9	0-79 (0-67-0-92)	Bion (2013) ¹¹⁸	1.8	0.49 (0.37-0.64)
Young (2006) ⁸⁶	1.5	0-33 (0-20-0-53)	Ceballos (2013)106	0.3	0.10 (0.01-0.80)
Bonello (2008)35	1.5	0-72 (0-43-1-19)	Chandonnet (2013)107	- 0.3	0.99 (0.12-8.44)
Costello (2008)94	1.4	0-54 (0-31-0-94)	Esteban (2013)%	1.0	0.57 (0.24-1.37)
Koll (2008)53	1.9	0-53 (0-45-0-61)	Exline (2013) ⁴¹	1.2	0.74 (0.37-1.48)
Santana (2008)74	1-0	0-57 (0-24-1-33)	Fisher (2013) 108	1-4	0.29 (0.16-0.52)
Duane (2009) ³⁹	1.4	0-67 (0-38-1-18)	Hocking (2013)	0-8	0.74 (0.25-2.20)
Gurskis (2009) ⁵⁷	0-4	0-29 (0-06-1-50)	Hong (2013)48	1.8	1-03 (0-76-1-39)
Zingg (2009)88	1-0	0-25 (0-11-0-58)	aggi (2013) ⁴⁹	1.8	0.53 (0.40-0.70)
Bizzarro (2010) ³⁰⁴	1-0	0-20 (0-09-0-46)	Jeong (2013) ¹¹⁹	0.9	0-31 (0-12-0-78)
Chuengchitraks (2010)93	0-2	0-96 (0-09-10-54)	Khalid (2013) ⁵¹	0.8	0.15 (0.05-0.43)
Lobo (2010) ⁵⁷	0-6	0-35 (0-10-1-24)	Leblebicioglu (2013)54 -	1.8	0.70 (0.54-0.90)
Marra (2010)59 -	1.7	0-50 (0-35-0-71)	Lin (2013) ²⁰	1-6	0.42 (0.27-0.65)
Miller (2010)61	1.3	0-40 (0-21-0-76)	Matthias Walz (2013)121*	0.9	0.06 (0.02-0.14)
Palomar (2010)65	1.7	0-57 (0-41-0-80)	Osorio (2013)63	0.8	0.59 (0.20-1.75)
Peredo (2010)67	1.1	0-36 (0-16-0-80)	Palomar (2013)64	1-8	0.50 (0.39-0.63)
Rosenthal (2010) ¹²³ *	1.7	0-46 (0-33-0-63)	Rosenthal (2013) ³¹⁴	1-7	0.45 (0.33-0.63)
Venkatram (2010) ⁷⁹	1.0	0-15 (0-07-0-36)	Berenholtz (2014) ³²	2.0	0.72 (0.69-0.75)
Vilela (2010) ¹⁰³	1.1	0-30 (0-14-0-65)	Hansen (2014) ⁴⁵	1-9	0.72 (0.58-0.88)
Wirtschafter (2010) ¹¹⁶	1.9	0-75 (0-67-0-89)	Sacks (2014) ⁷³	0.7	0.32 (0.09-1.08)
Espiau (2011) ⁹⁵	1.1	0.70 (0.21_1.55)	Thom (2014) ⁷⁸	1.3	0.20 (0.15-0.56)
Gozu (2011) ⁶	0-8	0.12 (0.05-0.27)	Zingg (2014) ¹⁰	0.6	0.21 (0.08-1.16)
Kim (2011) ^S	1.8	0.02 (0.02-0.04)	Allen (2014) ⁹⁰	1.3	0.37 (0.10-0.77)
Kime (2011) ¹¹¹	0-3	0.18 (0.02-0.04)	Tang (2014) ⁸⁹	0.0	0.30 (0.15-0.08)
Longmate (2011) ⁵⁸	0-0	0-24 (0.12-0.80)	Reddy (2014) ¹²⁵	1.8	0.86 (0.65-1.12)
Luiz Abramczyk (2011) ⁹⁸	1.2	0.52(0.28-1.01)	Latif (2015) ¹²⁴	1.8	0.60 (0.53-0.03)
Miller-Hoover (2011) ¹⁰⁰	0.6	0.30 (0.07-1.19)	7bou (2015) ¹¹⁷	0.0	0.46 (0.18-1.10)
Render (2011) ⁷⁰	2.0	0.29(007-118)	Pandom effects model	100-0	0.44(0.20,0.50)
Records (2011) ¹¹³	1.5	0.65 (0.59-0.71)	Heterogeneity: /2-80%	100.0	0.44 (0.39-0.50)
Schulman (2011) ¹¹⁵	1.9	0.62 (0.37-1.04)	heterogeneity.1 = 09%		
Scholman (2011)	1.0	0-00 (0-40-0-75)	0-01 0-10 1-00 10	0-00 100-00	
0.01 0.10 1.00 10.00	100-00		Environ O/Churdler Environ		
Favours CVC bundles Favours cont	rol		Favours CV C bundles Favour	IS CONTROL	
			IRR (95% CI)		
INV (32% CI)					



Preventing CRBSIs and other complications from CVCs



RISK FACTORS EQUIPMENT ENVIRONMENT Central Vascular Catheters (CVCs) can cause catheter Surfaces used for any CVC procedures e.g. during dressing Use only single-use sterile equipment, with intact nonstained, non-wet packaging that is within its expiry date. changes, must be visibly clean. related blood stream infections (CRBSIs) by enabling microorganisms to gain direct access to the blood stream. as well as single use vials. The areas where intravenous drugs are compounded (prepared) Ensure there is a selection of CVCs, sterile gloves, must be free from dutter and possible splash contamination and Microorganisms can originate from: the patient's skin at the masks, gowns and headwear, skin antiseptic containing risk assessed as suitable. insertion site, hub contamination: the hands of healthcare 2% chlorhexidine* gluconate in 70% isopropyl alcohol. workers (HCWs). sterile transparent semi-permeable dressings, 70% Additionally, poor drug preparation can result in infusate isopropyl alcohol and sterile body drapes available. contamination and can lead to CRBSI. Keep the equipment in a clean dry area where it will not Patients requiring CVCs may be vulnerable e.g. patients be subject to possible splash contamination. in ICUs: those undergoing cancer therapy; or long term Be alert to the efficacy of the dressing used e.g. any treatment such as renal dialysis. patient allergies, efficiency of the adhesive to provide a The duration of CVC use, poor insertion and maintenance. good seal. actions also increases the risk of infection Preventing CRBSIs and other complications from CVCs HEALTHCARE WORKERS (HCWs) METHODS (Insertion) METHODS (Maintenance) Only use a CVC if it is clinical necessary to do so. Ensure that the need for the CVC in situ is reviewed and recorded today (on Participate in programmes designed to optimise care. Consider using an insertion checklist to ensure the procedure is including training. a daily basis) performed correctly. Ensure the CVC dressing is intact. HCWs must be competent in the prevention of CRBSIs Aim to keep the number of needle passes to less than three. Ensure that the CVC dressing has been changed in the last seven days. and committed to minimising them by: Select a CVC most appropriate for patient's management. Ensure that 2% chlorhexidine" gluconate in 70% isopropyl alcohol is used for Removing CVCs as soon as possible. Ensure that surgical scrub is performed immediately before donning cleaning the insertion site during dressing changes. Performing all CVC procedures aseptically. Ensure that hand hygiene is performed immediately before accessing the maximal sterile barrier precautions (i.e. gloves and gown). Documenting all CVC procedures. Ensure that maximal sterile barrier precautions are used: including line/site (WHO Moment 2). Listening to and observing patient for signs of headwear, mask, sterile gown and sterile gloves for healthcare workers. Ensure that an antiseptic containing 70% isopropyl alcohol is used to clean infection. · Acting on locally available data. Ensure that maximal sterile barrier precautions are used by applying a the access hub prior to accessing - rub the access hub for at least 15 sterile body drape. seconds ('scrub the hub'). There should be visible, documented signs that the Use aseptic technique for all CVC administration manipulations / procedures. clinical team is committed to patient safety. This can be Ensure aseptic technique is maintained throughout insertion of CVCs. Ensure 2% chlorhexidine* in 70% isopropyl alcohol is used for skin Consider the use of a chlorhexidine* impregnated sponge dressing, e.g. by the collection and display of data in the clinical area preparation of the insertion site and allowed to dry, before CVC insertion. based on current infection rates on compliance with procedures and outcome rates (from Ensure the subclavian site is used if possible, or internal iugular vein participation in CRBSI surveillance) to inform positive Designate one port for TPN (if required). (femoral site should be avoided whenever possible). Have a planned scheduled change of the administration set minimum 72 hrs. discussions on how to optimise the care provided. Ensure that a sterile, transparent, semi-permeable dressing is used to max 96 hours or 24 hours if lipid or blood transfusions are used. cover the catheter site. Monitor the patient's temperature and pulse for signs of a CRBSI; report any abnormal findings in the patient or at the line site.

http://www.mhra.gov.uk/Publications/Safetywamings/MedicalDeviceAlerts/CON197918



- CAUTI is : A urinary tract infection (significant bacteriuria plus symptoms and/or signs attributable to the urinary tract with no other identifiable source) in a patient with current urinary tract catheterization or who has been catheterized in the past 48 hours
- Most common HAI worldwide resulting in increased costs, hospital stays, and substantial morbidity¹
- Avoidable with the implementation of bundles of care²
- General strategies to prevent CAUTI include : appropriate use, aseptic insertion and maintenance, early removal, and hand hygiene³

1. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50(5): 625-63.

2. Umscheid CA, Mitchell MD, Doshi JA, et al. Estimating the Proportion of Healthcare-Associated Infections that are Reasonably Preventable and the Related Mortality and Costs. Infect Control Hosp Epidemiol. 2011; 32(2):101–14. doi: 10.1086/657912.

3.Lo E, Nicolle LE, Coffin SE, et al. Strategies to Prevent Catheter- Associated Urinary Tract Infections in Acute Care Hospitals: 2014 Update. Infect Control International Conference

on Antimicrobial Resistance (ICAMR)

CAUTI Bundles



condom catheters, intermittent catheterization, use of nappies. Vising an aseptic Using an aseptic technique for insertion and proper maintenance after insertion.

> - Following evidencebased guidelines and implementing catheter insertion policies at the institution.

n Daily assessment of the presence and need for catheters.

- Urinary retention
- Monitor urine output

in unstable patients.

- To assist perineal

wound care.

Multimodal approach of hand hygiene, healthcare worker education, and feedback of catheter use and CAUTI rates

Saint S, Greene MT, Krein SL, et al. A Program to Prevent Catheter-Associated Urinary Tract Infection in Acute Care. N Engl J Med. 2016;374(22):2111–9.



1. Aseptic insertion

- Proper maintenance and dependant drainage
- Condom or intermittent catheterization in appropriate patients
- 4. Catheter required (Daily Assessment)



PROPER MAINTENANCE



DEPENDENT DRAINAGE





Meta-analysis of rate ratios for catheter-associated urinary tract infection episodes per 1000 catheter days, for intervention versus control groups, stratified by type of intervention to prompt catheter removal.



Meddings J et al. BMJ Qual Saf 2014;23:277-289

Copyright © BMJ Publishing Group Ltd and the Health Foundation. All rights reserved.

BMJ Quality & Safety



Resistance (ICAMR)

- VAP- New pneumonia occurring > 48 hours after endotracheal intubation
- In 20% of patients receiving mechanical ventilation¹
- Associated with increased antibiotic use, length of hospitalization and healthcare costs¹
- Mortality 20% to 50%, and attributable mortality is estimated at 13%²
- Over half the cases of VAP may be preventable with evidence-based strategies, with an impact on mortality³

1.Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and Economic Consequences of Ventilator-Associated Pneumonia: a Systematic Review. Crit Care Med. 2005; 33(10):2184–93.

2. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable Mortality of Ventilator-Associated Pneumonia: a Meta-Analysis of Individual Patient Data from Randomised Prevention Studies. Lancet Infect Dis. 2013; 13(8):665–71. doi: 10.1016/S1473-3099(13)70081-1. 3. Umscheid CA, Mitchell MD, Doshi JA, et al. Estimating the Proportion of Healthcare-Associated Infections that are Reasonably Preventable and the Related Mortality and Costs. Infect Control Hosp Epidemiol. 2011; 32(2):101–14. doi: 10.1086/657912.

VAP Care Bundles



- Elevate the head of the bed to between 30 and 45 degrees
- Daily "sedation interruption" and daily assessment of readiness to extubate
- Prophylaxis for peptic ulcer disease
- Prophylaxis for deep venous thrombosis
- Daily oral care with chlorhexidine
- Utilization of endotracheal tubes with subglottic secretion drainage (only for patients ventilated for longer than 24 hours)
- Initiation of safe enteral nutrition within 24-48 hours of ICU admission

Hand hygiene and Gloves

Adequate disinfection and maintenance of equipment and devices





ELEVATION OF HEAD-END OF BED



DAILY SEDATION VACATION AND ASSESSMENT OF READINESS TO EXTUBATE







Table 4. Associations Between Processes of Care and Patient Outcomes

	Outcome, HR (95% CI)							
Process of Care	Time to Extubation Alive	P Value	Ventilator Mortality	P Value	Time to Hospital Discharge Alive ^a	P Value	Hospital Mortality ^a	P Value
Head-of-bed elevation	1.38 (1.14-1.68)	.001	0.86 (0.59-1.25)	.42	1.01 (0.96-1.05)	.80	0.98 (0.93-1.03)	.36
Sedative infusion interruptions	1.81 (1.54-2.12)	<.001	0.51 (0.38-0.68)	<.001	1.09 (1.05-1.14)	<.001	0.92 (0.88-0.96)	<.001
Spontaneous breathing trials	2.48 (2.23-2.76)	<.001	0.28 (0.20-0.38)	<.001	1.00 (0.98-1.02)	.92	0.99 (0.96-1.02)	.46
Prophylaxis								
Thromboembolism	2.57 (1.80-3.66)	<.001	1.39 (0.82-2.37)	.23	1.02 (0.97-1.07)	.41	0.97 (0.92-1.02)	.26
Stress ulcer	1.12 (0.95-1.32)	.17	0.91 (0.64-1.31)	.62	1.00 (0.98-1.03)	.89	1.00 (0.96-1.04)	.90
Oral care with chlorhexidine	0.92 (0.80-1.04)	.18	1.63 (1.15-2.31)	.006	0.99 (0.98-1.01)	.26	1.01 (0.98-1.05)	.44

Abbreviation: HR, hazard ratio.

^a Analyses are restricted to patients who survived mechanical ventilation.

Klompas M, Li L, Kleinman K, Szumita PM, Massaro AF. Associations Between Ventilator Bundle Components and Outcomes. *JAMA Intern Med.* 2016;176(9):1277–1283.



Monitor and measure effectivity of bundle

- Calculate the VAP Rate
 - Numerator: No. of VAP cases
 - Denominator: Total ventilator days
 - Multiply by 1,000 to convert to a rate
- Calculate the compliance with Ventilator Bundle
 - Numerator: No. of vented patients receiving ALL components of bundle
 - Note: This is an "all or nothing" measure: a patient who had 1, 2 or 3 (not all) of the elements would count as a "no".
 - Denominator: Total No. of patients on ventilators for the day of the prevalence sample

2nd Internatio Confere



		N	laintenance Bu	indle for Ventil	ator (Care				
Day		erence hand giene Assessment of Readiness to Extubate (Done or	PUD	DVT	Daily oral care with Chlorhexidine			Sugnasted	Signa	iture
	Adherence Readin to hand Extu hygiene (Dor no		prophylaxis Needed or not	prophylaxis Given or not				VAP	Doctor	Nurse
		noty			6 am	12 noon	6 pm			
1										
2										1
3										

		Ma	intenance Bundle fo	or Central li	ine Care			
	Daily Catheter	Care by As	eptic technique	Any local signs of infection	Whether Dressing changed or not		Signature	
Day	Alcohol hub decontamination during handling	Hand hygiene before handling	Chlorhexidine gluconate 2%for insertion site dressing changes			CVC still required or not	Doctor	Nurse
1								
2								
3								

		Mai	intenance Bundle f	or Urinary C	Catheter Care		
Day	Daily Cat	heter Care by A	septic technique	Closed Drainage system (Yes/No)	Drainage bag	Catheter	Signature
	(Vaginal c	are/ Meatal card	e) + Perineal care		below bladder lever (Yes/No)	Needed (Yes/No)	
	6 am	12 noon	6 pm				
1							
2							
3							



- Develop a sedation protocol
- Develop a weaning protocol
- Create a pre-extubation worksheet to assess the risk of failed extubation
- Spread the use of ventilator bundle to other ICU's in your hospital

Bundle for the prevention of surgical site infection (SSI)

ICAMR UAE 2019

Conference on Antimicrobial Resistance (ICAMR)

- SSIs: infections of the incision or organ or space that occur after surgery
- SSIs complicate ~1.9% of surgical procedures in US¹ and 10% in African countries with a 9.7% case fatality rate²
- Half of SSIs are preventable³

1.Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017; 152(8):784–91. doi: 10.1001/jamasurg.2017.0904 2. Biscard BMA Madiba TE, Kluuta III. et al. Parimerative Patient Outcomes in the African Surgical Outcomes Study a 7 Day Prespective Observational Cabert Study Langet

2.Biccard BM, Madiba TE, Kluyts HL, et al. Perioperative Patient Outcomes in the African Surgical Outcomes Study: a 7-Day Prospective Observational Cohort Study. Lancet. 2018; pii: S0140- 6736(18)30001-1 2nd UAE

3. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999; 27(2):97–132; quiz 133–4

SSI Care Bundle

- Administration of parenteral antibiotic prophylaxis
- should be administered within 60 minutes prior to incision, including for Cesarean section25
- Re dosing is recommended for prolonged procedures, major blood loss or excessive burns 22
- Patients should be washed with soap or an antiseptic agent within a night prior to surgery
- Avoid hair removal: use electric clippers if necessary
- Use alcohol-based disinfectant for skin preparation in the operating room
- Maintain intraoperative glycemic control with target blood glucose levels < 200 mg/dL
- Maintain perioperative normothermia
- Administer increased fraction of inspired oxygen during surgery and after extubation in the immediate postoperative period in patients with normal pulmonary function

Hand hygiene, sterilization of surgical equipment, use of appropriate surgical attire, and staff education and feedback



Fig 2. Forest plot. Surgical care bundles to reduce the risk of surgical site infections.

Tanner J et al. Do surgical care bundles reduce the risk of surgical site infections in patients undergoing colorectal surgery? A systematic review and cohort meta-analysis of 8,515 patients. Surgery 2015; 158(1)

Health Protection Scotland Preventing cross transmission when an individual has known or suspected CDI



If a patient* has a known or suspected CDI

Patient with

Clostridium difficile infection

(CDI)

Ensure that:

- patients with CDI are isolated in a single room with en suite facilities or an allocated commode, until they are at least 48 hours symptom free and bowel
 movements have returned to patient's normal
- unnecessary antimicrobial treatment are stopped where this is indicated by local antimicrobial policy and that the antibiotic regimens of the patient with CDI is reviewed on a daily basis
- personal protective equipment (PPE) (i.e. gloves and aprons) is donned prior to, and subsequently removed, following each period of care activity for a
 patient with CDI
- the patient with CDI's immediate environment is cleaned at least daily using neutral detergent followed by a disinfectant containing 1000 parts per million (ppm) available chlorine(av cl) (or a combined detergent/disinfectant (1000ppm av cl))
- hand washing is performed after body fluid exposure during patient care and after touching a patient's surroundings following a period of care activity (WHO Moments 3 and 5)
- · ensure that patients have access to handwashing facilities and promote hand washing after patient uses toileting facilities and before eating
- · care equipment e.g. blood pressure cuffs, thermometers and stethoscopes is dedicated to a single patient with CDI whenever possible



Preventing CDI Cross-Transmission in Healthcare settings



RISK FACTORS

- Clostridium difficile infection (CDI) is the most common cause of intestinal infections associated with antimicrobial treatments which have been given to treat other infection and is recognised as an important cause of HAI. Presentation ranges in severity from mild diarrhoea to pseudomembranous colitis and toxic megacolon and CDI can result in death.
- The risk of CĎI is greater when patients with diarrhoea also have: current or recent use of antimicrobial agents, increased age, prolonged hospital stay, serious underlying diseases, surgical procedures (in particular bowel procedures), immunocompromising conditions or through use of proton pump inhibitors (PPIs).
- CDI produces spores that are difficult to eradicate from the environment. Cross transmission occurs through the faecal-oral route, via direct and indirect contact.

EQUIPMENT

- Ensure that care equipment e.g. blood pressure cuffs, thermometers and stethoscopes is dedicated to a single patient with CDI whenever possible.
- Equipment must be visibly clean, fit-for-purpose and capable of being effectively cleaned/decontaminated between uses.
- Ensure there is a selection of consumables including disposable gloves, disposable aprons, detergent and disinfectant (containing 1000 parts per million available chlorine) available, as well as adequate commodes.

ENVIRONMENT

- Surfaces should be clear from extraneous items to reduce the risk of contamination and aid cleaning.
- the patient with CDI's immediate environment is cleaned at least daily using neutral detergent followed by a disinfectant containing 1000 parts per million (ppm) available chlorine(av cl) (or a combined detergent/disinfectant (1000ppm av dl)). (Alcohol is ineffective against Clostridium difficile).

Preventing CDI Cross-Transmission in Healthcare settings

METHODS

- Ensure that patients with CDI are isolated in a single room with en suite facilities or an allocated commode, until they are at least 48 hours symptom free and bowel movements have returned to patient's normal.
- Ensure that PPE (i.e. gloves and aprons) is donned prior to, and subsequently removed, following each period of care activity for a patient with CDI. PPE must be put on before entering the room/ environment.
- Unnecessary antimicrobial treatment are stopped where this is indicated by local antimicrobial policy and that the antibiotic regimens of the patient with CDI is reviewed on a daily basis.
- Ensure that hand washing is performed after body fluid exposure during patient care and after touching patient's surroundings following a period of care activity (WHO Moment 3 and 5).
- Ensure that patients have access to handwashing facilities and promote hand washing after patient uses toileting facilities and before eating.

METHODS

- Ensure that a CDI care plan or similar is used to direct care.
- Ensure that a stool chart and a fluid balance chart are used. Report any abnormal findings.
- Monitor asymptomatic patients for possible relapse.
- Early diagnosis is essential with all wards/units; determine a baseline incidence of CDI and set a trigger that will ensure rapid targeted action.
- Clinical staff should review use of proton pump inhibitors (PPI).

HEALTHCARE WORKERS (HCWs)

- Should be aware of the availability of single rooms with en suite facilities for patients with CDI. When there is insufficient single rooms available, patients should be nursed in a cohort.
- Must be aware of CDI: symptoms, major risk factors, the trigger for their area, the
 actions required to prevent cross-transmission and outbreaks and the possibility of
 recurrence.
- Must follow the National Infection Prevention and Control Manual and local policies.
- Must obtain stool specimens from all patients 15 years and over with diarrhoea requesting testing for CD toxin as soon as possible or when suspected in younger patients.
- Must explain to the patient what CDI is, and seek the patient's and visitors cooperation in complying with infection control precautions.
- Infection Control Teams should undertake surveillance and feedback results locally to all relevant staff including managers.

Environmental cleaning Care Bundle The REACH Study

- Multicenter, randomized trial 11 acute care hospitals in Australia
- Intervention periods varied from 20 weeks to 50 weeks
- A multimodal intervention, focusing on optimizing product use, technique, staff training, auditing with feedback, and communication, for routine cleaning
- The primary outcomes were incidences of health-care-associated *Staphylococcus aureus* bacteraemia, *Clostridium difficile* infection, and vancomycin-resistant enterococci infection
- The secondary outcome was the thoroughness of cleaning of frequent touch points, assessed by a fluorescent marking gel

Mitchell B. et al. An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial. The Lancet Infectious Diseases (2019)

Table 1	Environmental	cleaning	bundle
---------	---------------	----------	--------

Bundle component	Key activities
Training	 Tailored training activities with environmental services staff at the commencement of the intervention phase, as part of induction for new cleaning staff, and as required throughout the intervention phase Content to reflect the trial site context and cleaning roles and responsibilities
Technique	 Attention to cleaning technique, including: A defined and consistent cleaning sequence A focus on cleaning high risk frequent touch points The use of sufficient pressure and movement Adherence to manufacturers' instructions for product use
Product	 Disinfectant minimally used for all discharge cleans and for daily cleans of high risk/precautions rooms Point of care wipes used for medical equipment
Audit	 Audit activities across the trial site using ultraviolet (UV) marker technology (all trial sites) and adenosine tri-phosphate (ATP) luminosity (3 trial sites) Regular audit feedback to cleaning staff Summarised audit results provided to clinical governance committees
Communication	 Promotion of a team approach Daily contact between cleaners and ward leaders or managers Cleaners represented on relevant clinical governance committees

Mitchell B. et. Lancet Infectious Diseases(2019)

Environmental cleaning Care Bundle The REACH Study

- Vancomycin-resistant enterococci infections reduced from 0.35 to 0.22 per 10 000 occupied bed-days (relative risk 0.63, 95% CI 0.41–0.97, p=0.0340)
- S aureus bacteremia (0.97 to 0.80 per 10 000 occupied bed-days; 0.82, 0.60–1.12, p=0.2180)
- *C difficile* infections (2·34 to 2·52 per 10 000 occupied bed-days; 1·07, 0·88–1·30, p=0·4655) did not change significantly
- The intervention increased the percentage of frequent touch points cleaned in bathrooms from 55% to 76% (odds ratio 2.07, 1.83–2.34, p<0.0001) and bedrooms from 64% to 86% (1.87, 1.68–2.09, p<0.0001)

The Most Effective Bundle Implementation

- Robust leadership
- Stringent protocols
- Participation of all members of the available healthcare team
- Reliable measurement of compliance
- Feedback of results
- The enablement of nursing staff to stop practice if the required protocols are not appropriately followed by other team members

Richards GA, Brink AJ, Messina AP, et al. Stepwise Introduction of the 'Best Care Always' Central-Line-Associated Bloodstream Infection Prevention Bundle in a Network of South African hospitals. J Hosp Infect. 2017; 97(1):86–92. doi: 10.1016/j.jhin.2017.05.013.

Ista E, van der Hoven B, Kornelisse RF, et al. Effectiveness of Insertion and Maintenance Bundles to Prevent Central-Line-Associated Bloodstream Infections in Critically III Patients of All Ages: a Systematic Review and Meta-Analysis. Lancet Infect Dis. 2016; 16(6):724–34. doi: 10.1016/S1473-3099(15)00409-0.



Lavallée et al. Implementation Science (2017) 12:142 DOI 10.1186/s13012-017-0670-0

Implementation Science

SYSTEMATIC REVIEW

The effects of care bundles on patient outcomes: a systematic review and metaanalysis

Jacqueline F. Lavallée^{1,2,3*}, Trish A. Gray^{1,2}, Jo Dumville^{1,2}, Wanda Russell⁴ and Nicky Cullum^{1,2,5}

Open Access



Study name	Outcome	Stati	stics for e	ach study		Ris	k ratio and 95%	CI	
		Risk ratio	Lower limit	Upper limit					
Anthony et al. (2011)*	SSIs	1.875	1.244	2.827	1		I		1
Chaboyer et al. (2016)*	HAPU	0.478	0.222	1.025		I –			
Chipps et al. (2016)*	MRSA/MSSA	0.447	0.146	1.365			-		
Jennings et al. (2015)*	Readmissions	0.849	0.475	1.518					
Loftus et al. (2012)*	Contamination	0.782	0.408	1.499					
Al-Tawfiq et al. (2010)	HAP/1000	0.269	0.067	1.083		_ _			
Anderson et al. (2015)	Pressure ulcers	0.133	0.041	0.428			_		
Antworth et al. (2013)	Candidemia	0.541	0.270	1.087					
Battersby et al. (2014a)	Exclusive MBM	0.978	0.931	1.027			_		
Battersby et al. (2014b)	Any MBM	0.932	0.860	1.009					
Berenholtz et al. (2011)	VAP/1000	0.083	0.005	1.490					
Boesch et al. (2012)	Trache-PU	0.037	0.001	1.402	-				
Conway-Morris et al. (2011)	VAP/1000	0.375	0.194	0.724		· I _	-		
Duzkaya et al. (2016)	CAUTI	0.295	0.056	1.552					
El Azab et al. (2013)	VAP/1000	0.340	0.130	0.890					
Eom et al. (2014)	VAP/1000	0.284	0.036	2.232					
Hakko et al. (2015)	CLABSI/1000	0.078	0.004	1.380	-				
Hocking & Pirrett (2013)	CLAB/1000	0.285	0.055	1.467					
Huddart et al. (2014)	Mortality	0.750	0.506	1.112					
Jeong et al. (2013)	CLABSI/1000	0.383	0.069	2.130		_			
Levy et al. (2014a)	Mortality	0.749	0.725	0.774					
Levy et al. (2014b)	Mortality	0.966	0.935	0.998					
Lim et al. (2015)	CAP mortality	0.648	0.428	0.981					
Lindsay et al. (2013)	Systolic BP	0.750	0.677	0.830					
Muzsynski et al. (2013)	VAT/1000	0.462	0.079	2.693			-		
Pena-Lopez et al. (2016)	VARI/1000	0.568	0.214	1.509		<u> </u>			
Rinke et al. (2013a)	CLABSI/1000	0.508	0.007	35.743	<	_	-		·
Rinke et al. (2013b)	Bacteraemia	0.465	0.021	10.177	-	_	•		
Salama et al. (2016)	CLABSI/1000	0.744	0.343	1.610					
Schindler (2009)	Pressure ulcers	0.362	0.205	0.638		<u> </u>			
Schweizer et al. (2015)	SSIs	0.668	0.443	1.007					
Silva Resende et al. (2011)	CABI/1000	0.618	0.326	1.172					
Stano et al. (2013)	MRSA/1000	0.163	0.052	0.513			-		
Steiner et al. (2015)	CLABSI/1000	0.338	0.119	0.959			•		
Stolbrink et al. (2014)	HAP	0.369	0.232	0.589		- 1	-		
Subramanian et al. (2013)	VAP/1000	0.385	0.213	0.693		I –	-	1	
					0.01	0.1	1	10	100

Favours care bundle

Favours usual care

Subgroup	Sta	tistics for	each	Risk ratio and 95% Cl	Overall subgroup difference
	Risk	Lower	Upper		
Health condition	ratio	limit	limit		
AP(n = 3.531)	0.38	0.26	0.57		
CLARSI (n=1 587)	0.46	0.26	0.8		
Pressure ulcers	0.40	0.20	0.52		
(n = 3,157)	0.55	0.21	0.52		$ ^2 = 86\%$
Other (n = 113,032)	0.79	0.71	0.89	♥	P = 0.03
Healthcare setting					
ICU (n = 42,314)	0.59	0.49	0.72	🔶	
Level 1 trauma centre (n = 925)	0.5	0.31	0.82		l ² = 86%
Other (n = 78,078)	0.78	0.67	0.91		P = 0.04
Elements					
2 (n = unclear)	0.78	0.37	1.67		
3 (n = 8,175)	0.64	0.48	0.85		
1 (n = 77,062)	0.71	0.57	0.89		
5 (n = 40,872)	0.67	0.57	0.79		l ² = 86%
ehaviour change echniques				1 1 1	P = 0.93
0 (n = 3,877)	0.7	0.53	0.92		
1 (n = 4,937)	0.67	0.48	0.93		
2 (n = 4,490)	0.49	0.33	0.75		
3 (n = 2,721)	0.44	0.3	0.65		
4 (n = 399)	0.6	0.43	0.84		
5 (n = 36,062)	0.85	0.66	1.1		
6 (n = 35,263)	0.84	0.66	1.1		
7 (n = unclear)	0.29	0.53	1.53		$ ^2 = 86\%$
8 (n = 520)	0.23	0.03	1.52		P < 0.05
Fidelity with care bundle					
Inadequate	0.79	0.65	0.96		
(<95%) (n = 70,911)	0.37	0.21	0.66		$l^2 = 86\%$ P = 0.03
Adequate (>95%) (n = 70,810)				0.01 0.1 1	10
				Favours care Favours	

bundle

usual care

Take Home Practice

- Your setting !
- Not 'silver bullet' solutions for all infections
- Targeted group of patients and in a common hospital location
- Concise, simple, and prescriptive (Institute for Healthcare Improvement)
- Not be static, but must adapt to changing evidence
- Obtain approval, commitment and endorsement from leadership, clinicians, nursing staff, and HCW
- Be clear on the purpose and collective goal of the desired process and communicate this message
- Identify members of the healthcare team to test the implementation of the proposed bundle elements
- Create awareness and provide the team with the applicable guidelines, evidence, toolkits and supplies
- Implement the interventions of each bundle element every time for every eligible patient
- Track compliance to the care bundle as an "all or nothing" measure and feedback results
- Adjust the delivery system and address logistical concerns
- Plan-Do-Study-Act (PDSA)
- Identify bundle champion or leader





Thank You